中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents

Incidence rates of hyperamylasemia and acute pancreatitis after percutaneous transhepatic biliary stenting and related risk factors

DOI: 10.3969/j.issn.1001-5256.2021.04.031
  • Received Date: 2020-09-15
  • Accepted Date: 2020-11-23
  • Published Date: 2021-04-20
  •   Objective  To investigate the clinical characteristics and risk factors of hyperamylasemia and acute pancreatitis after percutaneous transhepatic biliary stenting (PTBS).  Methods  A retrospective analysis was performed for the clinical data of 249 patients with malignant biliary obstruction who were admitted to Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, and underwent PTBS from March 2016 to February 2020, and according to the presence or absence of postoperative hyperamylasemia or acute pancreatitis, the patients were divided into two groups to analyze incidence rate, severity, and related risk factors. The t-test or the Mann-Whitney U test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. A multivariate logistic regression analysis was performed for the factors with P < 0.1 in the univariate analysis to investigate independent risk factors for hyperamylasemia and acute pancreatitis after PTBS.  Results  After PTBS, 55 patients (22.1%) patients had abnormally elevated serum amylase, among whom 26 (10.4%) were diagnosed with hyperamylasemia and 29 (11.7%) were diagnosed with acute pancreatitis. All patients with acute pancreatitis had mild manifestations. The multivariate logistic regression analysis showed that age ≤60 years (odds ratio [OR]=2.2, 95% confidence interval [CI]: 1.07-4.52, P=0.033), iodine-125 seed strand implantation (OR=2.8, 95%CI: 1.21-6.45, P=0.016), biliary stent placement across the papilla (OR=6.3, 95%CI: 2.85-14.05, P < 0.001), and visualization of the pancreatic duct during surgery (OR=13.9, 95%CI: 5.64-34.03, P < 0.001) were risk factors for hyperamylasemia and acute pancreatitis after PTBS.  Conclusion  Hyperamylasemia and acute pancreatitis are relatively common complications after PTBS. Age ≤60 years, iodine-125 seed strand implantation, biliary stent placement across the papilla, and visualization of the pancreatic duct during surgery are independence risk factors for hyperamylasemia and acute pancreatitis after PTBS.

     

  • loading
  • [1]
    WANG WJ, YU CH. Improvement in liver function in patients with malignant obstructive jaundice after endoscopic biliary metallic stent drainage[J]. J Clin Hepatol, 2015, 31(8): 1295-1298. DOI: 10.3969/j.issn.1001-5256.2015.08.027.

    王文君, 于聪慧. 胆道支架引流术对恶性梗阻性黄疸患者肝功能的影响[J]. 临床肝胆病杂志, 2015, 31(8): 1295-1298. DOI: 10.3969/j.issn.1001-5256.2015.08.027.
    [2]
    ZHANG K, ZHANG MF, REN JZ, et al. Efficacy of percutaneous intraductal radiofrequency ablation combined with biliary stenting in treatment of malignant biliary obstruction[J]. J Clin Hepatol, 2015, 31(5): 737-740. DOI: 10.3969/j.issn.1001-5256.2015.05.025.

    张凯, 张萌帆, 任建庄, 等. 经皮肝穿刺胆道腔内射频消融联合胆道支架治疗恶性胆道梗阻的临床观察[J]. 临床肝胆病杂志, 2015, 31(5): 737-740. DOI: 10.3969/j.issn.1001-5256.2015.05.025.
    [3]
    LEE SH, PARK JK, YOON WJ, et al. Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type[J]. World J Gastroenterol, 2007, 13(29): 3948-3955. DOI: 10.3748/wjg.v13.i29.3948.
    [4]
    CHEN BY, PANG LY. Implantation of biliary metallic stent for malignant obstructive jaundice: Technical comparison study between via ERCP route and via PTCD route[J]. J Intervent Radiol, 2016, 25(10): 880-884. DOI: 10.3969/j.issn.1008-794X.2016.10.011.

    陈保银, 庞林元. 两种不同途径胆道金属支架植入治疗恶性阻塞性黄疸的对比研究[J]. 介入放射学杂志, 2016, 25(10): 880-884. DOI: 10.3969/j.issn.1008-794X.2016.10.011.
    [5]
    PAN HW, WANG C, ZHANG Y. Risk factors of post-operative pancreatitis and hyperamylosis after endoscopic retrograde cholangiopancreatography[J]. China J Endosc, 2018, 24(7): 26-32. DOI: 10.3969/j.issn.1007-1989.2018.07.005.

    潘宏伟, 王晨, 张艳. 经内镜逆行胰胆管造影术后并发胰腺炎和高淀粉酶血症的危险因素分析[J]. 中国内镜杂志, 2018, 24(7): 26-32. DOI: 10.3969/j.issn.1007-1989.2018.07.005.
    [6]
    SUGAWARA S, ARAI Y, SONE M, et al. Frequency, severity, and risk factors for acute pancreatitis after percutaneous transhepatic biliary stent placement across the papilla of vater[J]. Cardiovasc Intervent Radiol, 2017, 40(12): 1904-1910. DOI: 10.1007/s00270-017-1730-1.
    [7]
    KIM ET, GWON DI, KIM JW, et al. Acute pancreatitis after percutaneous insertion of metallic biliary stents in patients with unresectable pancreatic cancer[J]. Clin Radiol, 2020, 75(1): 57-63. DOI: 10.1016/j.crad.2019.07.014.
    [8]
    BANKS PA, BOLLEN TL, DERVENIS C, et al. Classification of acute pancreatitis-2012: Revision of the Atlanta classification and definitions by international consensus[J]. Gut, 2013, 62(1): 102-111. DOI: 10.1136/gutjnl-2012-302779.
    [9]
    QIAN Z, LIU HC, PANG Q, et al. The clinical efficacy and prognostic factors of percutaneous biliary stent implantation combined with 125Ⅰ seed intracavitary irradiation in the treatment of cholangiocarcinoma[J]. Chin J Radiol, 2018, 52(8): 640-643. DOI: 10.3760/cma.j.issn.1005-1201.2018.08.014.

    钱震, 刘会春, 庞青, 等. 胆道支架联合125Ⅰ粒子腔内照射治疗胆管癌的临床疗效及预后因素分析[J]. 中华放射学杂志, 2018, 52(8): 640-643. DOI: 10.3760/cma.j.issn.1005-1201.2018.08.014.
    [10]
    YIN JY, YANG K. Nonsurgical treatment of malignant biliary obstructive diseases[J]. J Clin Hepatol, 2019, 35(3): 226-230. DOI: 10.3969/j.issn.1001-5256.2019.03.052.

    尹靖阳, 杨慷. 胆道恶性梗阻性疾病的非手术治疗[J]. 临床肝胆病杂志, 2019, 35(3): 681-685. DOI: 10.3969/j.issn.1001-5256.2019.03.052.
    [11]
    LIU R, HUANG K, CHEN WW, et al. Clinical effect of biliary stenting combined with percutaneous transhepatic cholangial drainage in treatment of different types of malignant obstructive jaundice[J]. J Clin Hepatol, 2019, 35(1): 131-137. DOI: 10.3969/j.issn.1001-5256.2019.01.025.

    刘锐, 黄坤, 陈伟伟, 等. 胆道支架植入术联合经皮肝穿刺胆管引流术治疗不同类型恶性梗阻性黄疸的效果观察[J]. 临床肝胆病杂志, 2019, 35(1): 131-137. DOI: 10.3969/j.issn.1001-5256.2019.01.025.
    [12]
    ZHAO XQ, DONG JH, JIANG K, et al. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: A meta-analysis[J]. Dig Endosc, 2015, 27(1): 137-145. DOI: 10.1111/den.12320.
    [13]
    KAWAKUBO K, ISAYAMA H, NAKAI Y, et al. Risk factors for pancreatitis following transpapillary self-expandable metal stent placement[J]. Surg Endosc, 2012, 26(3): 771-776. DOI: 10.1007/s00464-011-1950-4.
    [14]
    TELFORD JJ, CARR-LOCKE DL, BARON TH, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction[J]. Gastrointest Endosc, 2010, 72(5): 907-914. DOI: 10.1016/j.gie.2010.08.021.
    [15]
    KAHALEH M, TOKAR J, CONAWAY MR, et al. Efficacy and complications of covered Wallstents in malignant distal biliary obstruction[J]. Gastrointest Endosc, 2005, 61(4): 528-533. DOI: 10.1016/s0016-5107(04)02593-3.
    [16]
    KULLMAN E, FROZANPOR F, SÖDERLUND C, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: Results from a randomized, multicenter study[J]. Gastrointest Endosc, 2010, 72(5): 915-923. DOI: 10.1016/j.gie.2010.07.036.
    [17]
    COTÉ GA, KUMAR N, ANSSTAS M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents[J]. Gastrointest Endosc, 2010, 72(4): 748-754. DOI: 10.1016/j.gie.2010.05.023.
    [18]
    ARTIFON EL, SAKAI P, ISHIOKA S, et al. Endoscopic sphincterotomy before deployment of covered metal stent is associated with greater complication rate: A prospective randomized control trial[J]. J Clin Gastroenterol, 2008, 42(7): 815-819. DOI: 10.1097/MCG.0b013e31803dcd8a.
    [19]
    YOON WJ, LEE JK, LEE KH, et al. A comparison of covered and uncovered Wallstents for the management of distal malignant biliary obstruction[J]. Gastrointest Endosc, 2006, 63(7): 996-1000. DOI: 10.1016/j.gie.2005.11.054.
    [20]
    JO JH, PARK BH. Suprapapillary versus transpapillary stent placement for malignant biliary obstruction: Which is better?[J]. J Vasc Interv Radiol, 2015, 26(4): 573-582. DOI: 10.1016/j.jvir.2014.11.043.
    [21]
    TARNASKY PR, CUNNINGHAM JT, HAWES RH, et al. Transpapillary stenting of proximal biliary strictures: Does biliary sphincterotomy reduce the risk of postprocedure pancreatitis?[J]. Gastrointest Endosc, 1997, 45(1): 46-51. DOI: 10.1016/s0016-5107(97)70301-8.
    [22]
    COSGROVE N, SIDDIQUI AA, ADLER DG, et al. A comparison of bilateral side-by-side metal stents deployed above and across the sphincter of oddi in the management of malignant hilar biliary obstruction[J]. J Clin Gastroenterol, 2017, 51(6): 528-533. DOI: 10.1097/MCG.0000000000000584.
    [23]
    ZHANG JX, ZU QQ, LIU S, et al. Differences in efficacy of uncovered self-expandable metal stent in relation to placement in the management of malignant distal biliary obstruction[J]. Saudi J Gastroenterol, 2018, 24(2): 82-86. DOI: 10.4103/sjg.SJG_326_17.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Article Metrics

    Article views (708) PDF downloads(22) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return